Mostrar el registro sencillo del ítem
Emerging roles for high-density lipoproteins in neurodegenerative disorders
dc.contributor.author | Bahrami A. | |
dc.contributor.author | Barreto G.E. | |
dc.contributor.author | Lombardi G. | |
dc.contributor.author | Pirro M. | |
dc.contributor.author | Sahebkar A. | |
dc.date.accessioned | 2020-09-02T22:13:00Z | |
dc.date.available | 2020-09-02T22:13:00Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1002/biof.1541 | |
dc.identifier.citation | 45, 5, 725-739 | |
dc.identifier.issn | 09516433 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/3693 | |
dc.description | Lipoproteins are the complexes of different lipids and proteins, which are devoted to the transport and clearance of lipids or lipid-related molecules in the circulation. Lipoproteins have been found to play a crucial role in brain function and may influence myelination process. Among lipoproteins, high-density lipoproteins (HDLs) and their major protein component, apoA-I, are directly involved in cholesterol efflux in the brain. It has been suggested that inadequate or dysfunctional brain HDLs may contribute to cerebrovascular dysfunctions, neurodegeneration, or neurovascular instability. HDL deficiency could also promote cognitive decline through impacting on atherosclerotic risk. The focus of this review is to discuss knowledge on HDL dysregulation in neurological disorders. A better understanding on how changes in cellular HDL and apolipoprotein homeostasis affect central nervous system function may provide promising novel avenues for the treatment of specific HDL-related neurological disorders. © 2019 International Union of Biochemistry and Molecular Biology | |
dc.language.iso | en | |
dc.publisher | Blackwell Publishing Inc. | |
dc.subject | Alzheimer's disease | |
dc.subject | apolipoprotein | |
dc.subject | cholesterol | |
dc.subject | dementia | |
dc.subject | HDL | |
dc.subject | Parkinson's disease | |
dc.subject | apolipoprotein | |
dc.subject | high density lipoprotein | |
dc.subject | APOA1 protein, human | |
dc.subject | apolipoprotein A1 | |
dc.subject | cholesterol | |
dc.subject | high density lipoprotein | |
dc.subject | Alzheimer disease | |
dc.subject | central nervous system function | |
dc.subject | cognitive defect | |
dc.subject | degenerative disease | |
dc.subject | geriatric disorder | |
dc.subject | human | |
dc.subject | Huntington chorea | |
dc.subject | lipoprotein metabolism | |
dc.subject | nonhuman | |
dc.subject | Parkinson disease | |
dc.subject | priority journal | |
dc.subject | protein homeostasis | |
dc.subject | Review | |
dc.subject | atherosclerosis | |
dc.subject | blood vessel | |
dc.subject | brain | |
dc.subject | dementia | |
dc.subject | memory disorder | |
dc.subject | metabolism | |
dc.subject | pathology | |
dc.subject | transport at the cellular level | |
dc.subject | Alzheimer Disease | |
dc.subject | Apolipoprotein A-I | |
dc.subject | Atherosclerosis | |
dc.subject | Biological Transport | |
dc.subject | Blood Vessels | |
dc.subject | Brain | |
dc.subject | Cholesterol | |
dc.subject | Dementia | |
dc.subject | Humans | |
dc.subject | Huntington Disease | |
dc.subject | Lipoproteins, HDL | |
dc.subject | Memory Disorders | |
dc.subject | Parkinson Disease | |
dc.title | Emerging roles for high-density lipoproteins in neurodegenerative disorders | |
dc.type | Review |